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Purpose: Papaverine hydrochloride (PaHCl) is an old, well-known drug with spasmolytic 
activity but it has therapeutic effect in erectile dysfunction, too. As an intracavernous injection, 
it is not used in urologic clinics today because the side effects of the injection are pain, scar-
ring or priapism. Our aim was to develop and test a topical semi-solid preparation containing 
PaHCl that would provide an alternative administration option by eliminating the undesirable 
side effects of the injection.
Materials and methods: Lyotropic liquid crystal (LLC) systems were formulated as a 
semi-solid preparation with different concentrations of PaHCl. The characterization of the 
LLC structure was performed by polarization microscopy using a Leica image analyzer and 
rheological measurements. The drug diffusion and penetration tests were performed with in 
vitro synthetic membrane and an ex vivo human epidermis, using Franz diffusion cell to test 
the skin penetration of PaHCl. Human skin was investigated by Raman microscope to visualize 
the Active Pharmaceutical Ingredient (API) in different skin layers.
Results: The results of diffusion and penetration showed reverse concentration dependency. 
The in vitro and ex vivo studies correlated with each other and the results of Raman microscopy. 
The LLC structure influenced the penetration results, the lower viscosity and lamellar structure 
increased penetration through the skin.
Conclusion: Based on our results, a PaHCl containing topically used LLC formulation may 
be a suitable and effective alternative to the injectable formulation.
Keywords: nanocarrier, dermal penetration, impotence, Raman microscopy
Introduction
Erectile dysfunction (ED) is described as the persistent disability to attain and sustain 
an erection sufficient to permit satisfactory sexual performance.1,2 ED is a common 
disease. There are about 100 million men having ED worldwide. According to surveys, 
40% of men over the age of 40 have at least a slight degree of ED, which increases with 
progressing age.3 Epidemiological data have proved a high prevalence and incidence of 
ED in all countries. The real prevalence is hard to find out because a lot of people are 
ashamed of the problem. Because of this, up to 70% of men with ED are not treated. 
ED may change physical and psychosocial health, and may have an important influ-
ence on the quality of life of patients and their partners, too.4 There is evidence that 
ED can be an early sign of coronary artery and peripheral vascular disease.5
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The current therapeutic options for ED are the following.6 
In first-line treatment, oral phosphodiesterase-5 (PDE5) 
inhibitors are used. Classical drugs are sildenafil, vardenafil, 
and tadalafil, while the newest one is avanafil.7,8 These have 
many unwanted side effects, such as headache, nausea, dizzi-
ness. In second-line treatment, intracavernosal or intraurethral 
alprostadil therapy is used in patients who do not respond or 
are contraindicated for PDE5 inhibitors.9 Both methods are 
extremely uncomfortable for the patient; they are painful and 
involve significant financial difficulties as well as undesirable 
side effects, such as penis pain, hemorrhages, and burning 
in the urethra. To increase the small number of therapeutic 
options and to avoid unpleasant side effects, more and more 
research is directed at the transdermal entry gate.10–12
During topical treatment, if the active ingredient is 
delivered to the deeper layers of the skin, it is possible to 
penetrate into the corpus cavernosum by exerting the effect 
through the underlying vessels. The topical administration 
of drugs has many benefits compared to oral or injection 
applications. In the case of topical application, Active Phar-
maceutical Ingredients (APIs) avoid the first pass effect and 
better bioavailability becomes possible. There is no plasma 
peak concentration, so the incidence of side effects may be 
reduced. Moreover, topical use enables continuous drug 
delivery and patient compliance can also be improved with 
the Drug delivery systems of the preparation.13–19 In a 2015 
survey, 153 ED patients were asked to rank the different 
therapies from most to least desirable. The survey shows 
that there is a need for topical therapy because 53% of the 
people chose this application method first.20
Lyotropic liquid crystals (LLCs) have a number of benefi-
cial properties from the point of view of pharmaceutical tech-
nology. LLCs are usually formed of water, one or two tensides, 
and oil in a specified concentration and temperature range. 
They are suitable carrier systems for hydrophilic, lipophilic 
or amphiphilic drugs. They are extremely stable systems ther-
modynamically and can be maintained for a long time without 
the separation of the phases, so their structure is retained for a 
long time without structural changes. They also promote the 
penetration of the active substances through the skin, due to 
the low surface tension at the water–oil interface.21,22 Their 
use through the skin is especially advantageous, given the the 
concentration ratio of the components of LLC; the structure 
of the double lipid layer of the stratum corneum presents a 
similar lamellar structure and therefore their application can 
improve the penetration of the active ingredients.
Papaverine hydrochloride (PaHCl) is an old, well-known 
opium alkaloid. It is primarily used with spasmolytic indications 
in therapy. In 1982, a French surgeon, Ronald Virág discovered 
in Paris that PaHCl can be used as an intracavernosal 
injection.23 The injection with PaHCl was used for a long time 
as a second-line treatment but is not relevant today because 
of more discomfort or side effects for the patient.
A new drug delivery system with an old, well-known 
drug can be a promising combination to achieve the expected 
effect and improve the side effects profile. The aim of the 
present study was to prepare PaHCl containing LLC formula-
tions (PaHCl–LLC) with improved drug release properties 
(for the potential treatment of ED) and to characterize the 
formulation by means of techniques such as polarization 
microscopy and rheology measurement, and to model the 
skin penetration by a vertical Franz diffusion cell system 
and Raman microscopy.24,25
Materials and methods
Materials
The active ingredient, PaHCl was obtained from Hungaro-
pharma Ltd (Budapest, Hungary). The LLC was composed of 
two nonionic surfactants: Kolliphor RH40 (polyoxyl 40 hydro-
genated castor oil The United States Pharmacopeia- National 
Formulary [USP/NF]) was supplied by BASF SE Chemtrade 
GmbH (Ludwigshafen, Germany), and Tween 80 (polyoxy-
ethylene [20] sorbitan oleate) and an oil component, isopropyl 
myristate, were purchased from Merck (Budapest, Hungary).
Preparation of the samples
PaHCl was used in three different concentrations, 2.5, 3 and 
4 w/w% in the LLC systems. Drug-loaded LLCs were pre-
pared with the following procedure. PaHCl was dissolved in 
the hot water phase. Kolliphor RH 40 was melted, mixed with 
isopropyl myristate and Tween 80, and finally the aqueous 
phase was added in small portions to this mixture during gentle 
stirring to form the liquid crystals. A blank formulation were 
also prepared without PaHCl with the same procedure.
Polarization microscopy
To verify the special structure of the LLC composition, a 
polarization microscope was used (Leica Q500MC image 
processing and analyzing system, Leica Microsystems Cam-
bridge Ltd., Cambridge, United Kingdom) with crossed polar-
izers at room temperature. The magnification was 200×.
rheological investigations
Frequency-dependent oscillatory rheological measurements 
were performed with a Physica MCR101 rheometer to verify 
the structure of LLC systems and to differentiate the struc-
ture of compositions containing different concentrations of 
PaHCl. The storage (G′) and loss (G″) moduli were presented 
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in the function of the change of the frequency (0.01–100 Hz) 
within the linear viscoelastic range. The measurements were 
carried out at 32°C.
Drug diffusion and penetration studies
Vertical Franz diffusion cell (Hanson Microette TM 
Topical & Transdermal Diffusion Cell System, Hanson 
Research Corporation, Chatsworth, CA USA) was used to 
model the drug liberation from the LLCs and diffusion and 
penetration through in vitro synthetic membrane and ex 
vivo human heat separated epidermis. Excised human skin 
was obtained from a Caucasian female patient by routine 
plastic surgery procedure in the Department of Dermatol-
ogy and Allergology, University of Szeged. The ex vivo 
skin penetration test does not need ethical permission, and 
patient’s consent according to the Act CLIV of 1997 on 
health, Section 210/A in Hungary. The local ethical commit-
tee (Ethical Committee of the University of Szeged, Albert 
Szent-Györgyi Clinical Center) was informed about the ex 
vivo skin penetration studies (Human Investigation Review 
Board license number: 83/2008).
In the case of in vitro studies, 0.3 g of sample was placed 
as a donor phase on the synthetic membrane filter (Porafil 
membrane filter, cellulose acetate, pore diameter: 0.45 µm, 
Macherey-Nagel GmbH & Co. KG, Düren, Germany). In the 
case of ex vivo studies, heat-separated human epidermis was 
used as the membrane. The human skin was obtained from 
plastic surgery. As an acceptor phase, thermostated phosphate 
buffer (PBS pH 7.4±0.15) was used at 37°C±0.5°C. Mem-
brane diffusion and skin penetration experiments lasted 6 (in 
vitro) and 24 hours (ex vivo). The concentration of the drug 
was measured spectrophotometrically with a Thermo Scien-
tific Evolution 201 spectrometer with Thermo Insight v1.4.40 
software package (Thermo Fisher Scientific, Waltham, MA, 
USA) at a wavelength of 250 nm.
Treatment of human full thickness skin, 
tissue preparation and investigation with 
raman microscopy
Human subcutaneous fat free skin (epidermis and dermis) 
was used for the measurements. Approximately 1 cm2 of 
the skin surface was treated with the compositions for 6 
hours at 25°C and relative humidity 50%. The treated skins 
were frozen and sectioned (10 µm thick cross-sections) onto 
aluminum-coated slides using a Leica CM1950 cryostat (Leica 
Biosystems GmbH, Wetzlar, Germany). Before sectioning 
the skin samples, the LLCs were gently removed from the 
skin surface. Raman microscopic analyses were performed 
using a Thermo Scientific DXR Raman microscope (Thermo 
Fisher Scientific, Waltham, MA, USA). The 780 nm wave-
length laser light source was used, with a maximum power 
of 24 mW. The microscopic lens used for the measurements 
had 50× magnification, and the aperture of the pinhole was 
25 µm. In the case of chemical mapping, a 200×1,800 µm 
area was examined; the step size was 50 µm vertically and 
horizontally. Overall, 205 spectra were recorded, for collect-
ing each spectrum 16 scans were recorded, and the exposure 
time was 2 seconds. Instrument operation and the evaluation 
of measurements were done by the OMNIC for Dispersive 
Raman 8.2 software package (Thermo Fisher Scientific). The 
individual spectra of each component of LLC and PaHCl were 
used as a reference when comparing the treated vs untreated 
skin samples. For recording the individual spectra of the com-
ponents and LLCs, a 532 nm laser source was used. For each 
spectrum 32 scans were recorded with 6 seconds exposure 
time. In the Raman microscope, the magnitude of optics was 
10× with 25 µm slit aperture.
statistical analysis
The results were evaluated and analyzed statistically with 
the two-way analysis of variance test (Bonferroni’s multiple 
comparison), using Prism for Windows software (GraphPad 
Software Inc., La Jolla, CA, USA). The data are the averages 
of the results of at least five experiments ± standard deviation 
(P0.05, P0.01, and P0.001 vs the control).
Results and discussion
characterization of llc structure
results of polarization microscopy
The structures of the LLC samples were examined with a polar-
ization microscope. The LLC structure shows a special pattern 
(Maltese crosses) in polarized light. Maltese crosses repre-
sent the lamellar LLC structure.26 The Maltese crosses were 
detected in the blank LLC and the compositions containing 
2.5 and 3 w/w% of PaHCl. They were not detectable in the 
composition of 4 w/w% PaHCl. We assume that the increasing 
amount of dissolved PaHCl could have caused phase transition 
of LLC. The maltese crosses represent the lamellar structure. 
There was no detectable maltese crosses when the concentra-
tion of PaHCl is 4 (Figure 1D). Missing of maltese crosses 
show the structural transformation (Figure 1).
results of rheological measurements
The oscillation rheological measurements also justify the 
structural change (Figure 2). In the case of our LLC systems, 
the storage (G′) and loss (G″) moduli increase with increas-
ing concentration of PaHCl. The higher values of storage 
and loss moduli, with a higher order of magnitude, suggest 
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Figure 1 The polarization microscopic pictures of llc with different Pahcl concentrations.
Notes: (A) Blank llc; (B) 2.5 w/w% Pahcl–llc; (C) 3 w/w% Pahcl–llc; (D) 4 w/w% PaHCl–LLC. Magnification 200×.
Abbreviations: Pahcl, papaverine hydrochloride; llc, lyotropic liquid crystal.
$ %
& '
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P P
Figure 2 Oscillation rheological measurement.
Notes: (A) Blank llc; (B) 2.5 w/w% Pahcl–llc; (C) 3 w/w% Pahcl–llc; (D) 4 w/w% Pahcl–llc. g′: storage modulus; g″: loss modulus.
Abbreviations: Pahcl, papaverine hydrochloride; llc, lyotropic liquid crystal.
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that the LLC structure is intact after drug incorporation into 
the liquid crystal structure, altering the system’s properties, 
such as viscosity. The cubic phase is more viscous than the 
corresponding hexagonal or lamellar phases according to the 
literature.27 The increasing viscosity of the system may inhibit 
the release of the active substance from the given system, and 
it was assumed that the lamellar structure transformed into a 
cubic structure after the drug concentration was increased.
The microscopic and rheological studies confirm that 
PaHCl used in higher concentrations in the LLC system 
resulted in structural changes, and predict lower diffusion 
and penetration results.
results of drug diffusion and penetration
In vitro drug release through a synthetic membrane 
(Figure 3A) and ex vivo penetration through the human 
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Figure 3 in vitro drug diffusion, *p0.05 **p0.01 ***p0.001 vs 4w/w% Pahcl-llc (A) and ex vivo skin penetration, **p0.01 ***p0.001 vs 3w/w% Pahcl-llc 
(B) studies.
Abbreviations: Pahcl, papaverine hydrochloride; llc, lyotropic liquid crystal.
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epidermis (Figure 3B) were studied with vertical Franz dif-
fusion cell. In the case of the 2.5 w/w% PaHCl concentration, 
the membrane diffusion examinations showed the highest 
drug release and diffusion through the synthetic membrane 
in vitro, with 1,538±82 µg/cm2 being diffused over 6 hours.
The ex vivo drug penetration was lower through the 
human epidermis (251±53 µg/cm2 after 24 hours) in the 
case of all PaHCl concentrations because the ex vivo studies 
show not only the penetration through the human epidermis, 
which represents not only the diffusion profile of PaHCl but 
possibly interaction with the skin and the reservoir function 
of the stratum corneum as well.
When comparing the different PaHCl concentrations 
of the LLC composition, the results of diffusion in vitro 
and penetration ex vivo were similar. Generally speaking, 
the degree of diffusion and penetration increases with the 
increase of drug concentration. In this case, the best diffusion 
and penetration results were found with the smallest 2.5% 
concentration. These reverse membrane diffusion and skin 
penetration results supported the results of the structural 
analysis as well. The LLC system having a lower PaHCl 
concentration with a lamellar structure, and lower viscosity 
resulted in better diffusion and penetration.
results of raman microscopy
The spectra of PaHCl, the blank LLC and the three different 
formulations of PaHCL-LLC were recorded. In this case, the 
comparison of spectra was necessary, Figure 4A presents 
these results with the 4 w/w% PaHCl-LLC formulation. 
This result shows that PaHCl characteristic peaks appear in 
the PaHCL-LLC formulations, which proves that the API 
is enclosed in the LLC system. The Raman shift of these 
characteristic peaks are at around 1,606, 1,509, 1,409, 1,388, 
1,301, 770, 744, 713, 663, 647 and 361 cm−1. These shifts 
mostly denote the characteristic stretching and deforma-
tion vibrations of the PaHCl rings.28 These characteristic 
peaks and their regions are shown in Figure 4A and B, 
respectively.
After finding the characteristic vibrational peaks of 
PaHCl in the API-containing LLC system, the three different 
PaHCl-LLC formlations’ spectra were compared as shown 
in Figure 4B. The intensities of the characteristic PaHCl ring 
deformation and stretching vibrations increase with the increas-
ing concentration, according to Lambert-Beer’s law.
After obtaining information with Raman microscopy 
about the PaHCl containing LLC systems and evidence of 
the successful PaHCl intercalation into the LLCs, evaluation 
of the Raman measurements of the skin penetration was per-
formed. The correlation maps were produced, which showed 
the distribution of PaHCl by using the appropriate spectra 
for fitting to the treated skin spectra. As shown in Figure 4, 
PaHCl is easily determined from the LLC but the intensities 
of the characteristic peaks of PaHCl are very low. Therefore, 
the pure API’s spectrum could not be used for making the 
Figure 4 (Continued)
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acceptable correlation map. In this case, we had to assume 
the use of the PaHCl–LLC spectrum for making the skin 
distribution correlation maps, which indicates the presence 
of PaHCl as well. Thus, the correlation maps of the treated 
skin with three different amounts of PaHCl-containing LLCs 
were made by using the actual spectrum of the LLC systems. 
As control, a non-treated skin correlation map was evaluated. 
The results are shown in Figure 5.
The Raman correlation maps prove the presence of 
PaHCl–LLC in the different regions of the human skin. 
Figure 5 raman correlation maps for the distribution of Pahcl of different aPi concentration llcs in skin layers.
Abbreviations: Pahcl, papaverine hydrochloride; aPi, active pharmaceutical ingredient; llc, lyotropic liquid crystal.
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Abbreviations: Pahcl, papaverine hydrochloride; llc, lyotropic liquid crystal.
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In correlation with the ex vivo skin penetration results 
(Figure 4B), the most effective penetration is shown with the 
2.5 w/w% PaHCl-containing LLC; PaHCl could be found in 
the region of the dermis and the epidermis in the skin. With 
increasing PaHCl concentration, the penetration decreases. 
In correlation with the rheological investigations, the less 
effective LLC system is the highest PaHCl-containing LLC 
system. Therefore, as shown in Figure 5, the whole composi-
tion could be found only in the stratum corneum region in 
the skin and penetration was blocked.
Conclusion
The injectable delivery of PaHCl is hampered by several 
disadvantages including priapism, pain and low patient 
compliance; thus, this form is excluded from therapy. In the 
current research, different concentrations of PaHCl-loaded 
LLCs were formulated to investigate the transdermal penetra-
tion of the drug. Topically used PaHCl incorporated in the 
LLC delivery system is suitable for deep skin penetration; 
thus, the drug can reach the cavernous bodies by exerting the 
effect through the underlying vessels. In this study, samples 
of PaHCl used at lower concentrations of the liquid crystal-
line system showed better diffusion and penetration values. 
Structural studies have demonstrated that the structure of 
the system varies with increasing drug concentration. The 
formula that contains 2.5 w/w% of the API had the best 
characteristics. LLCs in the lamellar structure, characterized 
by lower concentrations, promote the diffusion of active 
ingredients throughout the skin. The Raman correlation maps 
complete the other ex vivo skin penetration measurement as 
a separate analysis.
Considering the average penis size, the surface on 
which the formulation can be used is ~89.16 cm2. Based 
on the best formulation results, more than 3,000 µg PaHCl 
penetrated into the dermis ex vivo in 1 hour. Compared to 
the dose of injection that was tailored individually (dose 
of injection individually titrated: 2,500–37,500 µg of 
active ingredient), our formulation may be a substitute for 
injection therapy.
It can be concluded that, in ex vivo circumstances, the 
LLC system with 2.5 w/w% of PaHCl concentration has great 
potential for helping drug permeation into the dermis, and 
efficacy of the topical treatment for ED can be predicted. The 
developed formula is suitable for clinical studies to prove 
its efficiency in ED.
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